Baseline Assessment and Monitoring for Ramipril Therapy

Baseline Evaluation

Obtain serum creatinine/eGFR, serum potassium, and a seated blood pressure measurement before starting ramipril, and repeat these labs 1–2 weeks after initiation to detect hyper‑kalemia or worsening renal function – European Society of Cardiology (ESC) Heart Failure Guidelines 2012; Circulation 2013; European Journal of Heart Failure 2012. 1, 2, 3
Additional routine screening recommended by hypertension guidelines includes fasting glucose (with HbA1c if elevated), a lipid panel, serum sodium, urinalysis with albumin‑to‑creatinine ratio, and a 12‑lead ECG – European Heart Journal 2024. 5

Absolute contraindications: prior ACE‑inhibitor‑induced angioedema, current or planned pregnancy, and bilateral renal artery stenosis – Circulation 2018; Circulation 2018; Circulation 2013; JACC 2018. 6, 7, 2, 8
High‑risk conditions requiring caution: systolic BP < 80 mm Hg, serum creatinine > 3 mg/dL, serum potassium > 5.0 mmol/L, or clinical volume depletion – Circulation 2013; ESC Heart Failure 2012; European Journal of Heart Failure 2012. 2, 9, 1, 3

Re‑measure renal function and serum potassium 1–2 weeks after the first dose – ESC Heart Failure 2012; Circulation 2013; European Heart Journal 2008; European Journal of Heart Failure 2012. 1, 2, 4, 3

Creatinine may rise up to 50 % above baseline or to a maximum of 266 µmol/L (≈3 mg/dL) provided eGFR remains ≥25 mL/min/1.73 m² – ESC Heart Failure 2012; European Journal of Heart Failure 2012. 1, 3
Serum potassium may increase to ≤5.5 mmol/L without requiring dose change – ESC Heart Failure 2012; European Journal of Heart Failure 2012. 1, 3

Halve the ramipril dose when:
- Creatinine rises to 266–310 µmol/L (3.0–3.5 mg/dL) or eGFR falls to 20–25 mL/min/1.73 m² – ESC Heart Failure 2012; European Journal of Heart Failure 2012.
- Potassium rises >5.5 mmol/L but remains <6.0 mmol/L – European Heart Journal 2008.
Stop ramipril immediately and obtain specialist input when:
- Creatinine doubles from baseline or exceeds 310 µmol/L (3.5 mg/dL) with eGFR < 20 mL/min/1.73 m² – ESC Heart Failure 2012; European Journal of Heart Failure 2012.
- Potassium exceeds 6.0 mmol/L – European Heart Journal 2008.
- Angioedema develops – ESC Heart Failure 2012.

After any dose titration, repeat renal function and potassium 1–2 weeks later – ESC Heart Failure 2012; European Heart Journal 2008; European Journal of Heart Failure 2012. 1, 4, 3
Following achievement of the maintenance dose, monitor labs at 1, 3, and 6 months – European Heart Journal 2008. 4
Thereafter, perform laboratory checks at least every 4 months – ESC Heart Failure 2012. 1
Patients with moderate‑to‑severe chronic kidney disease should have at least annual monitoring – European Heart Journal 2024. 5

For patients with creatinine clearance < 40 mL/min, initiate ramipril at 1.25 mg once daily (instead of the standard 2.5 mg) – European Heart Journal 2007. 10

Avoid concomitant NSAIDs (including OTC) because they increase the risk of renal dysfunction and hyper‑kalemia – ESC Heart Failure 2012; Circulation 2013; European Heart Journal 2008; European Journal of Heart Failure 2012. 1, 2, 4, 3
Do not use potassium supplements or potassium‑sparing diuretics unless specifically indicated, as they raise hyper‑kalemia risk – Circulation 2018; ESC Heart Failure 2012; Circulation 2013; European Journal of Heart Failure 2012. 6, 1, 2, 3
Never combine ramipril with ARBs or direct renin inhibitors because of potential harm – Circulation 2018; Circulation 2018; JACC 2018. 6, 7, 8

Assess volume status before starting ramipril and consider reducing diuretic dose if the patient is volume depleted to lower the risk of acute hypotension and renal injury – ESC Heart Failure 2012; European Journal of Heart Failure 2012. 1, 3

Monitoring recommendations are supported by high‑quality, class‑I evidence from the 2018 ACC/AHA Hypertension Guidelines, the 2012 ESC Heart Failure Guidelines, and the 2013 ACC/AHA Heart Failure Guidelines – Circulation 2018; Circulation 2018; JACC 2018; ESC Heart Failure 2012; European Journal of Heart Failure 2012; Circulation 2013. 6, 7, 8, 1, 3, 2